New Blockbuster Drugs to More Than Triple Acute Coronary Syndrome Treatment Market Value by 2023

 

August 5, 2014

August 5, 2014 — The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.

The company’s latest report states that across seven major markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape.

Amgen’s evolocumab, Sanofi and Regeneron’s alirocumab, and Pfizer’s bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and GlobalData expects these treatments to be launched in the middle of the forecast period.

Eric J. Dimise, Ph.D., GlobalData’s analyst covering cardiovascular and metabolic disorders, said, “These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment.” “The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40 percent of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion.”

GlobalData has also identified two new anticoagulants, Janssen’s Xarelto and Merck’s Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years.

Dimise said, “Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug’s mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015.

“The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential,” concluded the analyst.

For more information: www.globaldata.com